Selected research
Market Outlook & Growth Opportunities
Global Viral Vector-Based Cell & Gene Therapy CDMO Market Outlook and Growth Opportunities 2026
Market perspective
The global Viral Vector-Based Cell & Gene Therapy CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Viral Vector-Based Cell & Gene Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Viral Vector-Based Cell & Gene Therapy CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Viral Vector-Based Cell & Gene Therapy CDMO market include AGC Biologics, Lonza, Charles River Laboratories, Thermo Fisher Scientific, SK pharmteco and Exothera, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Viral Vector-Based Cell & Gene Therapy CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Viral Vector-Based Cell & Gene Therapy CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Viral Vector-Based Cell & Gene Therapy CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Viral Vector-Based Cell & Gene Therapy CDMO market.
Viral Vector-Based Cell & Gene Therapy CDMO Segment by Company
AGC Biologics
Lonza
Charles River Laboratories
Thermo Fisher Scientific
SK pharmteco
Exothera
Viral Vector-Based Cell & Gene Therapy CDMO Segment by Type
Adeno-associated Viral
Adenoviral
Lentiviral
Retroviral
Viral Vector-Based Cell & Gene Therapy CDMO Segment by Application
Gene Therapy
Cell Therapy
Vaccine Development
Viral Vector-Based Cell & Gene Therapy CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Viral Vector-Based Cell & Gene Therapy CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Viral Vector-Based Cell & Gene Therapy CDMO key companies, revenue, market share, and recent developments.
3. To split the Viral Vector-Based Cell & Gene Therapy CDMO breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Viral Vector-Based Cell & Gene Therapy CDMO market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Viral Vector-Based Cell & Gene Therapy CDMO significant trends, drivers, influence factors in global and regions.
6. To analyze Viral Vector-Based Cell & Gene Therapy CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector-Based Cell & Gene Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vector-Based Cell & Gene Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector-Based Cell & Gene Therapy CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Vector-Based Cell & Gene Therapy CDMO industry.
Chapter 3: Detailed analysis of Viral Vector-Based Cell & Gene Therapy CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Viral Vector-Based Cell & Gene Therapy CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Viral Vector-Based Cell & Gene Therapy CDMO in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends
Table 2. Viral Vector-Based Cell & Gene Therapy CDMO Industry Drivers
Table 3. Viral Vector-Based Cell & Gene Therapy CDMO Industry Opportunities and Challenges
Table 4. Viral Vector-Based Cell & Gene Therapy CDMO Industry Restraints
Table 5. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue Share by Company (2021-2026)
Table 7. Global Viral Vector-Based Cell & Gene Therapy CDMO Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Viral Vector-Based Cell & Gene Therapy CDMO Key Company Manufacturing Base & Headquarters
Table 9. Global Viral Vector-Based Cell & Gene Therapy CDMO Company, Product Type & Application
Table 10. Global Viral Vector-Based Cell & Gene Therapy CDMO Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Viral Vector-Based Cell & Gene Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Adeno-associated Viral
Table 15. Significant Companies of Adenoviral
Table 16. Significant Companies of Lentiviral
Table 17. Significant Companies of Retroviral
Table 18. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 19. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Type (2021-2026) & (US$ Million)
Table 20. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Type (2027-2032) & (US$ Million)
Table 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type (2021-2026)
Table 22. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type (2027-2032)
Table 23. Significant Companies of Gene Therapy
Table 24. Significant Companies of Cell Therapy
Table 25. Significant Companies of Vaccine Development
Table 26. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 27. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Application (2021-2026) & (US$ Million)
Table 28. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Application (2027-2032) & (US$ Million)
Table 29. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application (2021-2026)
Table 30. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application (2027-2032)
Table 31. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Region (2021-2026) & (US$ Million)
Table 33. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Region (2021-2026)
Table 34. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Region (2027-2032) & (US$ Million)
Table 35. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Region (2027-2032)
Table 36. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Country (2021-2026) & (US$ Million)
Table 38. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Market Share by Country (2021-2026)
Table 39. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Country (2027-2032) & (US$ Million)
Table 40. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Market Share by Country (2027-2032)
Table 41. AGC Biologics Company Information
Table 42. AGC Biologics Business Overview
Table 43. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
Table 45. AGC Biologics Recent Development
Table 46. Lonza Company Information
Table 47. Lonza Business Overview
Table 48. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 49. Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
Table 50. Lonza Recent Development
Table 51. Charles River Laboratories Company Information
Table 52. Charles River Laboratories Business Overview
Table 53. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 54. Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
Table 55. Charles River Laboratories Recent Development
Table 56. Thermo Fisher Scientific Company Information
Table 57. Thermo Fisher Scientific Business Overview
Table 58. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 59. Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
Table 60. Thermo Fisher Scientific Recent Development
Table 61. SK pharmteco Company Information
Table 62. SK pharmteco Business Overview
Table 63. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 64. SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
Table 65. SK pharmteco Recent Development
Table 66. Exothera Company Information
Table 67. Exothera Business Overview
Table 68. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 69. Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
Table 70. Exothera Recent Development
Table 71. Research Programs/Design for This Report
Table 72. Authors List of This Report
Table 73. Secondary Sources
Table 74. Primary Sources
List of Figures
Figure 1. Viral Vector-Based Cell & Gene Therapy CDMO Product Image
Figure 2. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032) & (US$ Million)
Figure 4. Global Viral Vector-Based Cell & Gene Therapy CDMO Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Adeno-associated Viral Image
Figure 8. Adenoviral Image
Figure 9. Lentiviral Image
Figure 10. Retroviral Image
Figure 11. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 12. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share 2021 VS 2025 VS 2032
Figure 13. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type (2021-2032)
Figure 14. Gene Therapy Image
Figure 15. Cell Therapy Image
Figure 16. Vaccine Development Image
Figure 17. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 18. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share 2021 VS 2025 VS 2032
Figure 19. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application (2021-2032)
Figure 20. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 21. Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 22. North America Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 23. North America Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 24. Europe Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 25. Europe Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 26. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 27. Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 28. South America Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 29. South America Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 30. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032) & (US$ Million)
Figure 31. Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country (%), 2025 VS 2032
Figure 32. USA Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 33. USA Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 34. USA Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 35. Canada Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 36. Canada Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 37. Canada Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 38. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 39. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 40. Mexico Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 41. Germany Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 42. Germany Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 43. Germany Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 44. France Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. France Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. France Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. U.K. Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. U.K. Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. U.K. Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Italy Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Italy Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Italy Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. Spain Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. Spain Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. Spain Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. Russia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. Russia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. Russia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. Netherlands Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. Netherlands Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. Netherlands Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. China Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. China Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. China Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. Japan Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. Japan Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. Japan Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. South Korea Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. India Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. India Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. India Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. Australia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. Australia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. Australia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. Brazil Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. Argentina Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. Argentina Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. Argentina Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Chile Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Chile Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Chile Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Colombia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Colombia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Colombia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Peru Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Peru Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Peru Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. Israel Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. Israel Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. Israel Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. UAE Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. UAE Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. UAE Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Turkey Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Iran Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Iran Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Iran Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. Egypt Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 114. Egypt Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 115. Egypt Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 116. Years Considered
Figure 117. Research Process
Figure 118. Key Executives Interviewed
Scope & coverage.
Types
- Adeno-associated Viral
- Adenoviral
- Lentiviral
- Retroviral
Applications
- Gene Therapy
- Cell Therapy
- Vaccine Development
Companies covered
- AGC Biologics
- Lonza
- Charles River Laboratories
- Thermo Fisher Scientific
- SK pharmteco
- Exothera
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Viral Vector-Based Cell & Gene Therapy CDMO Market Dynamics
- 2.1 Viral Vector-Based Cell & Gene Therapy CDMO Industry Trends
- 2.2 Viral Vector-Based Cell & Gene Therapy CDMO Industry Drivers
- 2.3 Viral Vector-Based Cell & Gene Therapy CDMO Industry Opportunities and Challenges
- 2.4 Viral Vector-Based Cell & Gene Therapy CDMO Industry Restraints
3 Viral Vector-Based Cell & Gene Therapy CDMO Market by Company
- 3.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Company Revenue Ranking in 2025
- 3.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Revenue by Company (2021-2026)
- 3.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Company Ranking (2024-2026)
- 3.4 Global Viral Vector-Based Cell & Gene Therapy CDMO Company Manufacturing Base and Headquarters
- 3.5 Global Viral Vector-Based Cell & Gene Therapy CDMO Company Product Type and Application
- 3.6 Global Viral Vector-Based Cell & Gene Therapy CDMO Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Viral Vector-Based Cell & Gene Therapy CDMO Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Viral Vector-Based Cell & Gene Therapy CDMO Market by Type
- 4.1 Viral Vector-Based Cell & Gene Therapy CDMO Type Introduction
- 4.1.1 Adeno-associated Viral
- 4.1.2 Adenoviral
- 4.1.3 Lentiviral
- 4.1.4 Retroviral
- 4.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Type
- 4.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Type (2021-2032)
- 4.2.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type (2021-2032)
5 Viral Vector-Based Cell & Gene Therapy CDMO Market by Application
- 5.1 Viral Vector-Based Cell & Gene Therapy CDMO Application Introduction
- 5.1.1 Gene Therapy
- 5.1.2 Cell Therapy
- 5.1.3 Vaccine Development
- 5.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Application
- 5.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Application (2021-2032)
- 5.2.3 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application (2021-2032)
6 Viral Vector-Based Cell & Gene Therapy CDMO Regional Value Analysis
- 6.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Region (2021-2032)
- 6.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Region: 2021-2026
- 6.2.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032)
- 6.3.2 North America Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032)
- 6.4.2 Europe Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032)
- 6.6.2 South America Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Country, 2025 VS 2032
7 Viral Vector-Based Cell & Gene Therapy CDMO Country-level Value Analysis
- 7.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Country (2021-2032)
- 7.2.1 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Country (2021-2026)
- 7.2.2 Global Viral Vector-Based Cell & Gene Therapy CDMO Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.7.2 France Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.14.2 China Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.17.2 India Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Viral Vector-Based Cell & Gene Therapy CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 AGC Biologics
- 8.1.1 AGC Biologics Company Information
- 8.1.2 AGC Biologics Business Overview
- 8.1.3 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.1.4 AGC Biologics Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- 8.1.5 AGC Biologics Recent Developments
- 8.2 Lonza
- 8.2.1 Lonza Company Information
- 8.2.2 Lonza Business Overview
- 8.2.3 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.2.4 Lonza Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- 8.2.5 Lonza Recent Developments
- 8.3 Charles River Laboratories
- 8.3.1 Charles River Laboratories Company Information
- 8.3.2 Charles River Laboratories Business Overview
- 8.3.3 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.3.4 Charles River Laboratories Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- 8.3.5 Charles River Laboratories Recent Developments
- 8.4 Thermo Fisher Scientific
- 8.4.1 Thermo Fisher Scientific Company Information
- 8.4.2 Thermo Fisher Scientific Business Overview
- 8.4.3 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.4.4 Thermo Fisher Scientific Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- 8.4.5 Thermo Fisher Scientific Recent Developments
- 8.5 SK pharmteco
- 8.5.1 SK pharmteco Company Information
- 8.5.2 SK pharmteco Business Overview
- 8.5.3 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.5.4 SK pharmteco Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- 8.5.5 SK pharmteco Recent Developments
- 8.6 Exothera
- 8.6.1 Exothera Company Information
- 8.6.2 Exothera Business Overview
- 8.6.3 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Revenue and Gross Margin (2021-2026)
- 8.6.4 Exothera Viral Vector-Based Cell & Gene Therapy CDMO Product Portfolio
- 8.6.5 Exothera Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst